Monte Rosa Therapeutics, Inc.

GLUE

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001826457

SEC filings (opens in a new tab)

In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.

Q1 2025 vs. Q4 2024

How the institutions holding Monte Rosa Therapeutics, Inc. changed between Q4 2024 and Q1 2025.

All holders in Q1 2025 All holders in Q4 2024

13F holders of GLUE: Q4 2024 compared with Q1 2025
Measure	Q4 2024	Of which not filed for Q1 2025	Q1 2025	Change
Holders	105	1	106	+2
Shares	61.0M	102.8K	59.5M	−1.36M (−2.2%)
Value	$423.3M	$713.7K	$276.2M	−$146.4M (−34.6%)

1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.

New holders (23)

Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.

Institutions new to GLUE in Q1 2025
Institution	Shares	Value	% of portfolio
Readystate Asset Management LP	287,000	$1.33M	0.07%
AQR Capital Management LLC	229,536	$1.07M	0.00%
Nuveen, LLC	117,672	$546.0K	0.00%
ExodusPoint Capital Management, LP	96,345	$447.0K	0.01%
Verition Fund Management LLC	51,725	$240.0K	0.00%
Brevan Howard Capital Management LP	37,574	$174.3K	0.00%
Graham Capital Management, L.P.	32,586	$151.2K	0.00%
Fox Run Management, L.L.C.	27,394	$127.1K	0.02%
Trexquant Investment LP	26,188	$121.5K	0.00%
UBS Asset Management Americas Inc	24,100	$111.8K	0.00%
Virtus Investment Advisers, Inc.	21,073	$97.8K	0.03%
Acadian Asset Management LLC	16,385	$76.0K	0.00%
Gsa Capital Partners LLP	15,162	$70.0K	0.01%
TownSquare Capital, LLC	11,391	$52.9K	0.00%
Lazard Asset Management LLC	7,595	$35.0K	0.00%
Simplex Trading, LLC	6,756	$31.0K	0.00%
Group One Trading, L.P.	5,398	$25.0K	0.00%
Zurcher Kantonalbank (Zurich Cantonalbank)	1,853	$8.60K	0.00%
Larson Financial Group LLC	409	$1.90K	0.00%
Coldstream Capital Management Inc	355	$1.65K	0.00%
Parkside Financial Bank & Trust	95	$441	0.00%
SRS Capital Advisors, Inc.	95	$441	0.00%
True Wealth Design, LLC	23	$107	0.00%

Sold out (21)

Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.

Institutions that sold out of GLUE in Q1 2025
Institution	Shares, Q4 2024	Value, Q4 2024
Citadel Advisors LLC	778,386	$5.40M
Norges Bank	445,868	$3.09M
Vestal Point Capital, LP	425,000	$2.95M
Jump Financial, LLC	154,842	$1.07M
Cubist Systematic Strategies, LLC	92,818	$644.2K
D. E. Shaw & Co., Inc.	70,114	$486.6K
Long Corridor Asset Management Ltd	40,000	$277.6K
Walleye Capital LLC	39,647	$275.1K
Squarepoint Ops LLC	31,654	$219.7K
Rafferty Asset Management, LLC	27,698	$192.2K
Two Sigma Advisers, LP	26,000	$180.4K
SG Americas Securities, LLC	16,742	$116.0K
Jane Street Group, LLC	14,581	$101.2K
Sherbrooke Park Advisers LLC	14,476	$100.5K
Janney Montgomery Scott LLC	13,315	$92.0K
Virtus ETF Advisers LLC	9,126	$63.3K
Toronto Dominion Bank	800	$5.55K
R Squared Ltd	300	$2.08K
Point72 Asset Management, L.P.	250	$1.74K
Caitong International Asset Management Co., Ltd	37	$257
US Bancorp	26	$180

Not filed for Q1 2025 yet (1)

Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding GLUE in Q4 2024 that haven't filed for Q1 2025
Institution	Shares, Q4 2024	Value, Q4 2024
Nuveen Asset Management, LLC	102,835	$713.7K